Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Marstacimab by Pfizer for Hemophilia A (Factor VIII Deficiency): Likelihood of Approval
Marstacimab is under clinical development by Pfizer and currently in Pre-Registration for Hemophilia A (Factor VIII Deficiency). According to GlobalData,...
Marstacimab by Pfizer for Hemophilia B (Factor IX Deficiency): Likelihood of Approval
Marstacimab is under clinical development by Pfizer and currently in Pre-Registration for Hemophilia B (Factor IX Deficiency). According to GlobalData,...
Risk adjusted net present value: What is the current valuation of Pfizer's Marstacimab?
Marstacimab is a monoclonal antibody commercialized by Pfizer, with a leading Pre-Registration program in Hemophilia B (Factor IX Deficiency). According...